Thermo Fisher Scientific announced the completion of its acquisition of Clario Holdings, a provider of endpoint data solutions for clinical trials, for $8.875B in cash, plus potential additional earnout and other payments, largely dependent on performance. With the transaction complete, the Clario business will become part of Thermo Fisher’s Laboratory Products and Biopharma Services segment.
Clario’s industry-leading solutions are highly complementary to Thermo Fisher’s clinical research offerings, enabling customers to gain critical insights from patient data to improve decision-making, accelerate innovation and drive greater productivity. Clario integrates clinical trial endpoint data from devices, sites and patients, enabling customers to collect, manage and analyze clinical evidence digitally across every phase of drug development, supporting faster, more confident trial decisions. The company’s platform has supported approximately 70% of FDA and EMA novel drug approvals over the past decade.
“We are excited to welcome Clario’s talented colleagues to Thermo Fisher,” said Marc N. Casper, chairman and chief executive officer of Thermo Fisher Scientific. “Clario is an outstanding strategic fit for our company, enhancing our ability to enable faster, more informed drug development through differentiated technology and data intelligence solutions.”
The attractive financial profile of Clario and expected synergy realization make the returns on this transaction very compelling with a double-digit internal rate of return. The business is expected to grow in the high single digits and is accretive to Thermo Fisher’s adjusted operating margin.
As previously announced, the acquisition is expected to contribute $0.45 of adjusted earnings per share (EPS)1 in the first year after close. Details on the positive impact on Thermo Fisher’s 2026 financials will be provided on the upcoming first quarter earnings call.
Thermo Fisher continues to expect to realize approximately $175M of adjusted operating income from synergies by year 5 following close, primarily from revenue synergies that the combined capabilities will unlock.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!